Dashboard/VKTX/dapiglutide/event

ReadoutTopline Readout

Dapiglutide VENTURE-3 Topline (Phase 3 Obesity)

VKTX·dapiglutide·Obesity·

Phase 3

·NCT06049498

current best date

'26

QTR4 months

Takeaway

Phase 3 weight-loss trial of Viking’s dual GLP-1 / GIP injectable in obese adults. Comparators in the same class: tirzepatide ~21% mean weight loss at 72 weeks; semaglutide ~15% at 68 weeks. Watch: % body-weight reduction at primary endpoint, GI tolerability, discontinuation rate.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

2 readouts

ClinicalTrials.gov

Stage base rate

~58%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAdual GLP-1 / GIP receptor agonist

dapiglutide (VK2735) is Viking Therapeutics' dual GLP-1/GIP receptor agonist in development for weight management in adults with obesity. The drug mimics two gut hormones — GLP-1 and GIP — that regulate appetite and blood sugar, prompting the brain to reduce food intake and the body to use energy more efficiently. Viking is evaluating both a once-weekly subcutaneous injection and a daily oral formulation, targeting a competitive profile against semaglutide and tirzepatide in the Phase 3 VENTURE trial.

Indication

Obesity / GLP-1

Obesity

MeSH · D009765

No primer in glossary yet.

Trial

recruiting

NCT06049498 ↗

VENTURE-3: Phase 3 Study of Dapiglutide in Obesity

Glossary · what this readout is measuring

2 terms detected in the takeaway

GLP-1target
Glucagon-like peptide-1
Gut hormone that triggers insulin release and slows gastric emptying. GLP-1 receptor agonists (semaglutide, tirzepatide) drive weight loss and glycemic control.
GIPtarget
Glucose-dependent insulinotropic polypeptide
Companion gut hormone to GLP-1. Dual GLP-1/GIP agonists (tirzepatide) produce larger weight loss than GLP-1 alone.

Sector base rates · reference data

historical record · not prediction

of 3 historical Phase 3 readouts in Obesity / GLP-1: 2 positive, 1 mixed, 0 negative.

Positive

2/ 3

67%

Mixed

1/ 3

33%

Negative

0/ 3

positive rate 67% · primary endpoint hit rate 100%

Reference data · comparable readouts

How Ph3 readouts in Obesity / GLP-1 have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

2/3

67% in record

Primary endpoint hit

100%

across 3 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

cagrisema

NVO · Obesity

Ph3 · Dec 2024mixed−22.7% — below internal 25% bar8-K

semaglutide 50mg oral

NVO · Obesity

Ph3 · May 2023positive−15.1% body weight at 68 wkPR

tirzepatide (SURMOUNT-1)

LLY · Obesity

Ph3 · Apr 2022positive−22.5% body weight at 72 wk vs −2.4% pboPR

AMG 133 (maritide)

AMGN · Obesity

Ph2 · Nov 2024mixed−20% body weight — high GI AE rate8-K

VK2735

VKTX · Obesity

Ph2 · Feb 2024positive−14.7% body weight at 13 wkPR

retatrutide

LLY · Obesity

Ph2 · Jun 2023positive−24.2% body weight at 48 wkconference

orforglipron

LLY · Obesity

Ph2 · Jun 2023positive−14.7% body weight at 36 wkconference

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

2 peers in Obesity / GLP-1 · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Phase	Next catalyst
RM-718	RYTM	peptide	weekly MC4R agonist (next-gen)		READOUT · Oct 26
IMCIVREEsetmelanotide	RYTM	peptide	MC4R agonist		PDUFA · Aug 26

Disclosure trail

2 observations · sorted by confidence

Feb 14, 2026·2mo agopinned · highest confidence
HIGH conf8-K
top claim
Q3'26
QTR↗ 62dvs prior
“Following the completion of additional enrollment cohorts, the Company now expects to report VENTURE-3 topline data in the second half of 2026, with results most likely in the fourth quarter.”
contextItem 7.01 Regulation FD Disclosure — analyst-day deck excerpt.
conf 93%via llm
Feb 28, 2026·2mo ago
HIGH conf10-K
other claim
Q3'26
QTR
“We expect to report topline data from our Phase 3 VENTURE-3 study of dapiglutide in obesity in the third quarter of 2026.”
contextFrom the Pipeline section of Viking Therapeutics 10-K, fiscal year ended December 31, 2025.
conf 91%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.